ISSN 1662-4009 (online)

ey0017.5-2 | Advances in Clinical Practice | ESPEYB17

5.2. Osteogenesis Imperfecta: Skeletal outcomes after bisphosphonate discontinuation at final height

ME Robinson , P Trejo , T Palomo , FH Glorieux , F Rauch

To read the full abstract: J Bone Miner Res. 2019 Dec;34(12):2198–2204.In brief: In Osteogenesis imperfecta (OI), intravenous (IV) cyclical bisphosphonates are often discontinued after cessation of growth in adolescents. This study showed that, four years after discontinuation of treatment, none of the patients sustained new vertebral compression fractures, and the proportion ...

ey0018.12-10 | Metabolic Syndrome | ESPEYB18

12.10. Genome-wide discovery of genetic loci that uncouple excess adiposity from its comorbidities

LO Huang , A Rauch , E Mazzaferro , M Preuss , S Carobbio , CS Bayrak , N Chami , Z Wang , UM Schick , N Yang , Y Itan , A Vidal-Puig , M den Hoed , S Mandrup , TO Kilpelainen , RJF Loos

Nat Metab. 2021 Feb;3(2):228–243. doi: 10.1038/s42255-021-00346-2. PMID: 33619380.In brief: In this genome-wide association study, the authors were able to disentangle the mechanism that uncouples adiposity from its known cardiometabolic complications. They identified 62 genomic loci, at which the same allele is associated with both higher adiposity and lower cardiometabol...